The comparative study of quality of life and toxisities in patients with chronic myeloid leukemia during imatinib therapy vs. nilotinib therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OCH-11001699

Enrollment

Unknown

Registered

2011-11-08

Start date

2011-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myeloid leukemia

Interventions

one:imatinib

two:imatinib

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with chronic myeloid leukemia who received imatinib therapy vs nilotinib therapy

Exclusion criteria

Exclusion criteria: Patients with severe organ dysfunction

Design outcomes

Primary

Measure	Time frame
SF-36 health survey;	—

Countries

China

Contacts

Public ContactXiaojun Huang

xjhrm@medmail.com.cn+86 10 88326005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 23, 2026